← Back to patent-cliff list
Goserelin Microspheres for Injection(1-month long acting formulation,Luye Pharma)
Tier C — Watch / tradeGoserelin Microspheres for Injection(1-month long acting formulation,Luye Pharma)
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GnRHR
Indications (approved)：Breast cancer, Prostate cancer
Regional status
US
-
EU
-
China
Approved
2023-06-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Goserelin Microspheres for Injection(1-month long acting formulation,Luye Pharma)?
Approved indications include: Breast cancer, Prostate cancer.
When does the Goserelin Microspheres for Injection(1-month long acting formulation,Luye Pharma) patent expire?
No public expiry year is available for Goserelin Microspheres for Injection(1-month long acting formulation,Luye Pharma) yet; this page updates once verified.
How do I get a quote for Goserelin Microspheres for Injection(1-month long acting formulation,Luye Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27